Immunosuppressive therapies by Rituximab found to be Effecti
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
The aim of this research was to use cohort analysis to monitor the progression of MOG-ON and assess the therapeutic efficacy and tolerability of traditional immunosuppressants.

This bidirectional cohort study included 121 patients with MOG-ON. The clinical features and annualised relapse rate (ARR) of patients with and without IST were analysed.

Results:
--The median age at onset was 17.5 years, and the sex ratio (F:M) was 1.24.

--Of 121 patients, 77 patients relapsed and 61 patients were younger than 18 years at disease onset. The overall median ARR of 63 patients in the non-IST group was 0.5, with 46.0% patients showing relapse at a median follow-up of 33.5 months.

--In the IST group, the ARR decreased from 1.75 pre-IST to 0.00 post-IST in 53 patients who received IST exceeding 6 months, with 20.8% patients showing relapse at a median follow-up of 23.8 months.

--The relapse rates of patients treated with rituximab (RTX) and mycophenolate mofetil (MMF) were not statistically different, but the rate of discontinuation was significantly lower in the RTX-treated group (18.2% vs 57.7%).

Conclusively, this study provides Class III evidence that both MMF and RTX may lower disease activity in patients with MOG-ON, and RTX showed better tolerability than MMF. However, observation after a single attack remains a good option because less than half of patients not on treatment suffered a relapse.

Source: https://bjo.bmj.com/content/early/2021/04/29/bjophthalmol-2020-318769?rss=1
Like
Comment
Share